

ICH M10 GUIDELINE ADOPTION BY ANVISA

Dulcyane Neiva Mendes Fernandes

Coordination of Therapeutic Equivalence

EBF - November 20, 2020





Internal Governance for ICH

→ Ordinance (Portaria) 1.520/2019

➡ Service Orientation 75/2019





Internal Governance for ICH

Ordinance 1.520/2019 -> Ordinance with Anvisa's regulatory performance model for harmonizing and internalizing themes developed within the scope of ICH.

- Governance structure;
- Requirements for representatives participation;
- Responsibilities;

• Flow for harmonization and internalization of ICH themes -> detailing of activities will be in specific Service Orientation (OS).





Internal Governance for ICH

OS 75/2019 -> Service Orientation on the flow to harmonization and internalization of themes developed within the scope of ICH.

After adoption on ICH -> Anvisa Internalization of ICH Guideline

• Step 1: Identification of the national legal basis related to the theme.





Brazilian Legislation on Bioanalysis

- RE 895/2003 -> Guide for elaborate technical report of relative bioavailability/bioequivalence study.
- RE 1170/2006 -> Guide for medicines relative bioavailability/bioequivalence evidences.
- RDC 27/2012 -> Minimum requirements for the validation of bioanalytical methods used in studies for the purposes of medicine marketing authorization and post approval changes.






After adoption on ICH -> Anvisa Internalization of ICH Guideline

- **Step 2:** Internalization of ICH Guideline totally or partially.
- **Step 3:** Appropriate regulatory instrument for internalization.





Anvisa Regulatory Instruments





Anvisa Regulatory Instruments

NORMATIVE ACTION - REGULATION



Resolution of Collegiate Board (RDC)

RDC is the act expressing collegiate decision to issue rules on matters within the agency's scope with provision for sanction in case of non-compliance.



Normative Instruction

Normative instruction is the act that expresses a normative decision of the collegiate board for the purpose of detailing rules and procedures of external scope, established in RDC.





After adoption on ICH -> Anvisa Internalization of ICH Guideline

- **Step 4:** Assessment of the need for a new consultation with external agents.
- **Step 5:** Deadline for internalization, including deadline for document translation.
- **Step 6:** Need to change or revoke a normative act.





Brazilian Legislation on Bioanalysis

- RE 895/2003 -> Guide for elaborate technical report of relative bioavailability/bioequivalence study -> tables and attachments
- RE 1170/2006 -> Guide for medicines relative bioavailability/bioequivalence evidences -> no impact
- RDC 27/2012 -> Minimum requirements for the validation of bioanalytical methods used in studies for the purposes of medicine marketing authorization and post approval changes -> almost all





1. Introduction

- 1.1. Objective
- 1.2. Background
- 1.3. Scope

2. General principles

- 2.1. Method development
- 2.2. Method validation
 - 2.2.1 Full validation
 - 2.2.2 Partial validation
 - 2.2.3 Cross validation





- 3. Chromatography
 - 3.1. Reference standards
 - 3.2. Validation
 - 3.2.1 Selectivity
 - 3.2.2 Specificity
 - 3.2.3 Matrix effect
 - 3.2.4 Calibration Curve and Range
 - 3.2.5 Accuracy and Precision
 - 3.2.5.1 Preparation of Quality Control Samples
 - 3.2.5.2 Evaluation of Accuracy and Precision
 - 3.2.6 Carry-over
 - 3.2.7 Dilution integrity
 - 3.2.8 Stability
 - 3.2.9 Reinjection Reproducibility





3. Chromatography (continued)

- 3.3. Study sample analysis
 - 3.3.1 Analytical run
 - 3.3.2 Acceptance Criteria for an Analytical Run
 - 3.3.3 Calibration Range
 - 3.3.4 Reanalysis of Study Samples
 - 3.3.5 Reinjection of Study Samples
 - 3.3.6 Integration of Chromatograms

4. Ligand Binding Assays

- 4.1 Key reagents
 - 4.1.1 Reference standard
 - 4.1.2 Critical reagents







- 4. Ligand Binding Assays (continued)
 - 4.2. Validation
 - 4.2.1 Specificity
 - 4.2.2 Selectivity
 - 4.2.3 Calibration Curve and Range
 - 4.2.4 Accuracy and Precision
 - 4.2.4.1 Preparation of Quality Control Samples
 - 4.2.4.2 Evaluation of Accuracy and Precision
 - 4.2.5 Carry-over
 - 4.2.6 Dilution Linearity and Hook Effect
 - 4.2.7 Stability







4. Ligand Binding Assays (continued)

- 4.3. Study Sample Analysis
 - 4.3.1 Analytical Run
 - 4.3.2 Acceptance Criteria for an Analytical Run
 - 4.3.3 Calibration Range
 - 4.3.4 Reanalysis of Study Samples

5. Incurred Sample Reanalysis

6. Partial and Cross Validation

- 6.1 Partial Validation
- 6.2 Cross Validation











7. Additional Considerations

- 7.1 Analytes that are also Endogenous Compounds
 - 7.1.1 Quality Control Samples
 - 7.1.2 Calibration Standards
 - 7.1.3 Selectivity, Recovery and Matrix Effects
 - 7.1.4 Parallelism
 - 7.1.5 Accuracy and Precision
 - 7.1.6 <mark>Stability</mark>
- 7.2 Parallelism
- 7.3 Recovery







7. Additional Considerations (continued)

- 7.4 Minimum Required Dilution
- 7.5 Commercial and Diagnostics Kits
- 7.6 New or Alternative Technologies
 - 7.6.1 Dried Matrix Methods

8. Documentation

- 8.1 Summary Information
- 8.2 Documentation for Validation and Bioanalytical Reports

9. Glossary







After adoption on ICH -> Anvisa Internalization of ICH Guideline

- **Step 7:** The internalization plan must be submitted to DICOL's decision (fully approve, approve with reservations or request diligences from the organizational unit to carry out complementations).
- **Step 8:** After approval of the internalization plan, the ANVISA ICH coordinator must inform ICH secretariat of the way and deadlines defined by DICOL for internalization.





After adoption on ICH -> Anvisa Internalization of ICH Guideline

- Step 9: Elaboration of regulatory instrument (OS 56/2018).
 - Elaborate regulatory instrument;
 - Public consultation (analyze the contributions received and promote the relevant adjustments);
 - Legal analysis;
 - DICOL deliberation (approve, make adjustments, filing);
 - Publish the final regulatory instrument in the DOU.





Approval of ICH harmonised guideline of Bioanalytical method validation and study sample analysis -> november, 2021

After adoption by ICH, long way till its internalization in Anvisa.





Thank you!

dulcyane.mendes@anvisa.gov.br





Contacts

Agência Nacional de Vigilância Sanitária - Anvisa SIA Trecho 5 - Área especial 57 - Lote 200 CEP: 71205-050 Brasília - DF

www.gov.br/anvisa/pt-br

www.twitter.com/anvisa_oficial

Anvisa Atende: 0800-642-9782

ouvidoria@anvisa.gov.br ich.anvisa@anvisa.gov.br



